...
首页> 外文期刊>Bioconjugate Chemistry >N-Succinimidyl 3-[~(131)I] Iodo-4-phosphonomethylbenzoate ([~(131)I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs
【24h】

N-Succinimidyl 3-[~(131)I] Iodo-4-phosphonomethylbenzoate ([~(131)I]SIPMB), a Negatively Charged Substituent-Bearing Acylation Agent for the Radioiodination of Peptides and mAbs

机译:N-琥珀酰亚胺基3- [〜(131)I]碘-4-膦酰基甲基苯甲酸酯([〜(131)I] SIPMB),一种带负电荷的取代基酰化剂,用于肽和mAb的放射性碘化

获取原文
获取原文并翻译 | 示例
           

摘要

An important criterion in design of acylation agents for the radioiodination of internalizing monoclonal antibodies (mAbs) is to maximize the retention of radioiodine in the tumor following mAb intracellular processing. We have previously shown that labeling methods that generate positively charged catabolites have enhanced tumor retention. Herein we ahve extended this strategy to investigate the potential utility of labeling internalizing mAbs with an acylation agent that yielded labeled catabolites that would be negatively charged at lysosomal pH. The negatively charged acylation agent, N-succinimidyl 3-[~(131)I] iodo-4-phosphonomethylbenzoate ([~(131)I]SIPMB), was prepared from its tin precursor, N-succinimidyl 4-di-tert-butylphosphonomethyl-3-trimethylstannylbenzoate (tBu-SPMTB), in 40% radiochemical yield. The free acid, 3-[~(131)I] iodo-4-phosphonomethylbenzoic acid ([~(131)I]IPMBA), was also prepared from the corresponding precursor, 4-di-tert-butylphosphonomethyl-3-trimethyl-stannylbenzoic acid (tBu-PMTBA), in 80% radiochemical yield. The rapidly internalizing mAb L8A4 was conjugated to [~(131)I] SIPMB in 25-40% yield with preservation of its immunoreactivity. Internalization and processing in the U87DELTAEGFR glioma cell line was studied in a paired label format with L8A4 labeled with ~(125)I using the Iodogen method. Retention of initially bound radioactivity in these cells at 4 h from [~(131)I]SIPMB-labeled mAb was approximately 6-fold higher than that for directly labeled mAb. Catabolite analysis demosntrated that this difference reflected an order of magnitude higher retention of low molecular weight species in these cells. The [~(131)I] SIMPMB-L8A4 conjugate was intact over the first 2 h; thereafter, lysine-[~(131)I]SIPMB was the predominant catabolite. In contrast, L8A4 labeled using Iodogen rapidly gave rise to mono-[~(125)I] iodotyrosine within 2h, which then cleared rapidly from the cells. These results suggest that SIPMB could be a potent candidate for labeling internalizing mAbs and warrant further study.
机译:设计用于内化单克隆抗体(mAb)放射性碘化的酰化剂的重要标准是在单克隆抗体胞内加工后最大化放射性碘在肿瘤中的保留。先前我们已经表明,产生带正电荷的分解代谢物的标记方法具有增强的肿瘤保留能力。在本文中,我们扩展了该策略,以研究用酰化剂标记内在化单克隆抗体的潜在效用,该酰化剂产生标记的分解代谢物,这些分解代谢物在溶酶体pH值下带负电荷。带有负电荷的酰化剂N-琥珀酰亚胺基3- [〜(131)I]碘-4-膦酰基甲基苯甲酸酯([〜(131)I] SIPMB)是由其锡前体N-琥珀酰亚胺基4-二-叔丁基制备的。丁基膦酰基甲基-3-三甲基锡烷基苯甲酸酯(tBu-SPMTB),放射化学产率为40%。游离酸3- [〜(131)I]碘-4-膦酰基甲基苯甲酸([〜(131)I] IPMBA)也由相应的前体4-二叔丁基膦酰基甲基-3-三甲基-苯乙烯基苯甲酸(tBu-PMTBA),放射化学产率为80%。快速内在化的mAb L8A4以25-40%的产率与[〜(131)I] SIPMB偶联,并保留了其免疫反应性。使用Iodogen方法以配对标记形式研究了U87DELTAEGFR胶质瘤细胞系的内在化和加工过程,其中L8A4用〜(125)I标记。 [〜(131)I] SIPMB标记的mAb在这些细胞中最初绑定的放射性在4 h时的保留比直接标记的mAb高约6倍。分解代谢物分析表明,这种差异反映出低分子量物质在这些细胞中的保留率提高了一个数量级。 [〜(131)I] SIMPMB-L8A4共轭物在最初2小时内完整;此后,赖氨酸-[〜(131)I] SIPMB是主要的分解代谢产物。相反,用碘原标记的L8A4在2小时内迅速产生单-[〜(125)I]碘酪氨酸,然后迅速从细胞中清除。这些结果表明,SIPMB可能是标记内在化单克隆抗体的有效候选者,值得进一步研究。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号